<DOC>
	<DOC>NCT02454075</DOC>
	<brief_summary>This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison syndrome.</brief_summary>
	<brief_title>YF476 and Type II Gastric Carcinoids</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Zollinger-Ellison Syndrome</mesh_term>
	<mesh_term>Gastrinoma</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Inclusion criteria: 1. Men; postmenopausal women; premenopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophorectomy; or premenopausal women using one of the allowed methods of contraception: condom and spermicide or intrauterine device. 2. Patients with serum gastrin &gt;250 pg/mL. 3. Hepatic function: AST and ALT ≤2.0 x ULN; total bilirubin ≤1.0 x ULN. 4. Renal function: serum creatinine &lt;1.0 x ULN. 5. Haematologic function: Hb ≥10.0 g/dL; WBC ≥3.5 x 10e9 /L; ANC ≥1.5 x 10e9 /L; platelets ≥100 x 10e9 /L. 6. Coagulation parameters: INR or PT ≤1.0 x ULN; PTT ≤1.0 x ULN. 7. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial. 8. Willingness to give fullyinformed, written consent. Exclusion criteria: 1. Patients under 18 years. 2. Women who are pregnant, lactating or using a steroid contraceptive. 3. Prior gastric resection or bypass. 4. Planned gastrinoma resection during the study period. 5. Patients on somatostatin analogues, except for those on therapy for &gt;6 months with stable or worsening carcinoids. 6. Inability to tolerate endoscopy, or refusal of endoscopy. 7. Physical findings, ECG (especially prolonged QTc interval &gt;450 msec), or laboratory values at the pretrial screening assessment that could interfere with the objectives of the trial or the safety of the subject. 8. Certain medicines and herbal remedies taken during the 7 days before visit 2. 9. Participation in a trial of an IMP within the previous 28 days. 10. Presence of drug or alcohol abuse. 11. History or baseline findings of: type 1 diabetes mellitus; pancreatitis (baseline amylase and/or &gt;2.0 x ULN); hepatitis B, hepatitis C or HIV; malabsorption syndrome or inability to swallow or retain oral medicine; major surgery &lt;28 days prior to enrolment; ECOG performance staus &gt;2; or another cancer within 3 years except for basal carcinoma of the skin or cervical carcinoma insitu. Also, any clinically significant and uncontrolled major morbidity including but not limited to; serious cardiac disease (unstable angina, s/p myocardial infarction &lt;1 month); respiratory disease (advanced COPD or pulmonary fibrosis); uncontrolled hypertension; or active systemic infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>YF476</keyword>
	<keyword>netazepide</keyword>
	<keyword>gastric carcinoids</keyword>
	<keyword>Zollinger-Ellison syndrome</keyword>
</DOC>